NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

Phase 2

Suspended

Conditions: Osteosarcoma
Recurrent Osteosarcoma

Interventions: Procedure: Biospecimen Collection
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Biological: Trastuzumab Deruxtecan

First Posted Date: 2020-11-05

Last Posted Date: 2025-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 77

Registration Number: NCT04616560

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 25 locations

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Fallopian Tube Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Advanced Pancreatic Adenocarcinoma
Advanced Primary Peritoneal Carcinoma
Fallopian Tube High Grade Serous Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Ovarian High Grade Serous Adenocarcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Diagnostic Imaging Testing
Drug: Elimusertib
Drug: Gemcitabine

First Posted Date: 2020-11-05

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT04616534

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Phase 1

Recruiting

Conditions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Interventions: Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography Test
Drug: Lenalidomide
Procedure: Lumbar Puncture
Procedure: Magnetic Resonance Imaging
Drug: Methotrexate
Biological: Nivolumab
Procedure: Positron Emission Tomography
Biological: Rituximab
Procedure: Ultrasound Imaging

First Posted Date: 2020-10-30

Last Posted Date: 2025-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT04609046

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 45 locations

Connect for Cancer Prevention Study (Connect)

Recruiting

Conditions: Cancer
General Research Use

First Posted Date: 2020-10-30

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200000

Registration Number: NCT04609072

Locations: 🇺🇸
Baylor Scott and White Health, Dallas, Texas, United States
🇺🇸
Kaiser Permanente Colorado, Denver, Colorado, United States
🇺🇸
Kaiser Permanente Georgia, Atlanta, Georgia, United States

and more 7 locations

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Phase 1

Completed

Conditions: Mantle Cell Lymphoma
B-Cell Lymphoma
Marginal Zone Lymphoma
Chronic Lymphocytic Lymphoma
Follicular Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Venetoclax
Drug: Magrolimab
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Prednisone/prednisolone
Drug: Methylprednisolone
Diagnostic Test: CT Scan chest/abdomen/pelvis
Diagnostic Test: MRI
Diagnostic Test: 18-FDG-PET
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration

First Posted Date: 2020-10-23

Last Posted Date: 2025-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT04599634

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Phase 2

Active, not recruiting

Conditions: Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
Locally Advanced Gastrointestinal Stromal Tumor
Locally Advanced Sarcoma
Metastatic Gastrointestinal Stromal Tumor
Metastatic Sarcoma
Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Rogaratinib

First Posted Date: 2020-10-22

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT04595747

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 15 locations

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Phase 1

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: Olaparib
Biological: Trastuzumab Deruxtecan

First Posted Date: 2020-10-14

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04585958

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Pomalidomide Treatment in Patients With Kaposi Sarcoma

Phase 2

Active, not recruiting

Conditions: Skin Kaposi Sarcoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Pomalidomide
Procedure: X-Ray Imaging

First Posted Date: 2020-10-08

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT04577755

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Miami Cancer Institute, Miami, Florida, United States
🇺🇸
University of Illinois, Chicago, Illinois, United States

and more 12 locations

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3

Recruiting

Conditions: Metastatic Bladder Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Refractory Bladder Urothelial Carcinoma
Refractory Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Docetaxel
Drug: Eribulin Mesylate
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Biological: Sacituzumab Govitecan

First Posted Date: 2020-10-08

Last Posted Date: 2025-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 184

Registration Number: NCT04579224

Locations: 🇺🇸
Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States
🇺🇸
Greater Regional Medical Center, Creston, Iowa, United States
🇺🇸
Southwest Oncology PC, Durango, Colorado, United States

and more 428 locations

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Endometrial Carcinoma

Interventions: Procedure: Biopsy Procedure
Drug: Megestrol Acetate
Drug: Extended Release Metformin Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2020-10-06

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT04576104

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 5 locations

Home Terms & Conditions Privacy Policy